Seeking Alpha

nutmeg_bull

nutmeg_bull
Send Message
View as an RSS Feed
View nutmeg_bull's Comments BY TICKER:
Latest  |  Highest rated
  • Sangamo: A Fiery Biotech With A Product Poised To Go Down In Flames? [View article]
    In the years ahead, when Sangamo has relegated hemophilia and a host of other monogenic diseases to the ash heap of history, an "article" like this will seem even more blatantly one-sided and transparent than it already is. Ms. Colberg focuses on an HIV program that is only one aspect of Sangamo's work—one that likely will prove a life-extending adjuvant to current HAART therapy for a distinct set of patients-in-need. Even before the upcoming monogenic INDs in 2014, buyers have been scrambling for shares of this stock, because they know what a game-changer Sangamo's gene-altering therapeutic is likely to be. It is precisely at moments like this when spurious drive-by hit pieces like this one emerge, as shorts fear for their lives. As MineMan suggests, though, I hope the shorts temporarily have their day so that sensible investors can purchase Sangamo at an even more reasonable price than its current attractive valuation.
    Sep 21, 2013. 04:02 AM | 3 Likes Like |Link to Comment
  • Sangamo BioSciences Receives $6.4 Million Strategic Partnership Award From California Institute for Regenerative Medicine (CIRM) to Develop ZFP Therapeutic® for Beta-thalassemia [View article]
    If you have the stomach for the wild ride that Sangamo's HIV program will take shareholders on in the next few years, you virtually can count on the diseases that this little company certainly will cure in the years ahead.
    May 24, 2013. 08:40 AM | 1 Like Like |Link to Comment
  • Sangamo BioSciences: A Potentially Revolutionary 2013 [View article]
    Cecile writes, "Do you think the much reported of late Cas-9 RNA complex method will have an impact on Sangamo?"

    Absolutely. I think that Sangamo will treat CRISPRs much as they have TALENS. They will become familiar Cas-9 RNA editing and may even move in that direction if CRISPRs prove as safe in human beings as zinc finger editing is. That's the big question, though. Right now, zinc fingers are the gold standard and Sangamo holds the gold. Cas-9 RNA editing is an extrememly promising but nascent technique.
    Jan 16, 2013. 01:28 AM | Likes Like |Link to Comment
COMMENTS STATS
3 Comments
4 Likes